Indonesia ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

Indonesia Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Indonesia Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $177 Mn in 2022 and is projected to reach $316 Mn in 2030, exhibiting a CAGR of 7.5% during the forecast period. The 2023 State Budget Bill for Indonesia sets aside $200 Bn for State Expenditure, which includes transfers to the regions of $53 Bn and $150 Bn for Central Government spending. 5.6 % of state spending, or $11 Bn, goes toward the health fund. The National Health Insurance (JKN) program will be maintained, the health system will be reformed, stunting will be reduced more quickly, and the resources will be used to address the pandemic.

In the Indonesian capital, DKI Jakarta, a sizable portion of elementary school students (26.2%) experience ADHD. Their everyday functioning may be impacted by ADHD behaviors, which include off-task and on-task behaviors, peer interactions, and following instructions. These behaviors can be maladaptive to the social environment in the classroom or at home. Therefore, in the absence of adequate treatment, it may result in a number of psychosocial issues, including learning difficulties, poor scholastic performance, self-adjusting issues, substance abuse, and criminal behavior. ADHD is a disorder that can be safely and successfully treated. It carries significant morbidity, including a higher risk of teen drug abuse and mood disorders, if undertreated or untreated.  Some children may respond to behavioral interventions, occupational therapy, and extra school supports even though they don't fully fit the diagnostic criteria and aren't excellent candidates for medication. Emotional or behavioral problems, developmental disabilities, and other medical conditions are frequently present in children with ADHD.

Methylphenidate is the drug of choice used in Indonesia to address ADHD. Methylphenidate, a psychostimulant, helps children focus better while performing their duties while also reducing hyperactivity and impulsive behavior. In 80% of patients with ADHD, using stimulant medication is effective, but some patients do not react or are unable to handle the side effects, which include decreased appetite, sleep disturbances, mood instability, and an increase in comorbid conditions. The potential for abuse also exists, particularly in individuals with a history of drug abuse. The Federal Drug Administration (FDA) has approved atomoxetine hydrochloride, a norepinephrine reuptake inhibitor, for the treatment of ADHD in adults, teens, and children older than six years old. According to the findings of numerous studies, atomoxetine treatment may lower the severity of ADHD symptoms.

Market Dynamics

Market Growth Drivers

In Indonesia, knowledge of ADHD has improved, which has made it easier for parents and medical professionals to identify the signs of ADHD in adolescents. As a consequence, the number of diagnoses for ADHD has significantly increased in recent years. The prevalence of ADHD has increased in Indonesia as a result of urbanization and shifting lifestyles. People are exposed to a faster-paced lifestyle as more people migrate to urban areas, which can raise stress levels and cause symptoms of ADHD. In Indonesia, there has been an increasing emphasis on mental health, with more people becoming aware of its significance and seeking treatment for disorders like ADHD.

Market Restraints

The majority of studies have shown that there is still little understanding, perception, and attitude about ADHD in all societal categories in Indonesia. According to reports, most community members lack an adequate understanding of the causes and treatments for ADHD, which causes them to refuse to take medication because they believe medication is used excessively to treat the condition thereby limiting the growth of Indonesia's ADHD therapeutics market.

Competitive Landscape

Key Players

• Nufarindo (IDN)
• Bernofarm (IDN)
• Mega Lifesciences (IDN)
• Gratia Husada Farma (IDN)
• Etana Biotechnologies (IDN)
• Noven Pharmaceuticals
• Novartis
• Johnson & Johnson
• Curemark
• MonoSol
• KemPharm

Healthcare Policies and Regulatory Landscape

The Indonesian National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan - BPOM) is in charge of overseeing the laws governing drugs and medical equipment in the area under the direction of the Indonesian Ministry of Health (MOH). Manufacturers must navigate through the intricate regulatory processes, which include registration requirements, market authorizations, and regulatory requirements, in order to gain entry to the market. This entails the pre- and post-market assessment of products, as well as the licensing and certification of pharmaceutical industries based on Good Manufacturing Practices (GMP). Product sampling, lab testing, manufacturing and distribution facility inspections, research, and collaboration with law enforcement are all part of market monitoring. In order to confirm that product claims adhere to predetermined standards, the organization also assesses product advertisements and promotions. The BPOM is in charge of public education and communication regarding product safety as well as public alerts in the event that subpar goods enter the market. Last but not least, the organization is in charge of locating and pursuing drug counterfeiters in cooperation with law enforcement.